title: Effects of zoledronic acid and docetaxel on small GTP-binding proteins in prostate cancer.
abstract: Increasingly, in castration-resistant prostate cancer, patients are often treated with docetaxel and the bisphosphonate zoledronic acid concurrently, yet there is still a paucity in the literature regarding the molecular basis of how this drug combination works. The study was performed on the hormone-resistant cell line PC-3. Cells were treated with clinically relevant concentrations of docetaxel and zoledronic acid either as single agents or in sequence and combination. Cell viability and apoptosis were assessed along with the prenylation status of the GTPases Ras and RhoA. Following 1-mM zoledronic acid treatment, inhibition of the prenylation of H-Ras and Rho A was observed along with an increase in the unprenylated form in the cytoplasm. Docetaxel 1 nM and zoledronic acid 1 mM also showed an increase in the unprenylated form of both small GTP-binding proteins in the cytoplasm and a reduction of protein in the membrane fraction. Overall, zoledronic acid followed by docetaxel was the best regimen producing the greatest reduction in cell viability and increase in apoptosis. At the highest concentrations of zoledronic acid and docetaxel, zoledronic acid followed by docetaxel was also the most effective at reducing the prenylation of both H-Ras and RhoA at the membrane. We have demonstrated that clinically achievable concentrations of zoledronic acid and docetaxel cause a reduction in the prenylation of both H-Ras and Rho A and a reduction of protein movement into the membrane. The most effective regimen overall was high-dose zoledronic acid followed by docetaxel, suggesting that this regimen may be of benefit in clinical practice.
authors: Gynaecology Department, Velindre Cancer Centre, Cardiff, CF14 2TL, UK.
authors: Rachel M
authors: RM
authors: Jones
authors: Claire
authors: C
authors: Morgan
authors: Gianfilippo
authors: G
authors: Bertelli
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004164:Diphosphonates / Q000008:administration & dosage; D000077143:Docetaxel; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage; D000077211:Zoledronic Acid; D018631:ras Proteins / Q000096:biosynthesis*; D020742:rhoA GTP-Binding Protein / Q000096:biosynthesis*
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D043823:Taxoids; C066737:RHOA protein, human; D000077143:Docetaxel; D000077211:Zoledronic Acid; D018631:ras Proteins; D020742:rhoA GTP-Binding Protein
references: Clin Sci (Lond). 2005 Apr;108(4):293-308
references: 15603554
references: Cancer Res. 2001 Apr 15;61(8):3369-72
references: 11309294
references: J Biol Chem. 1995 Nov 10;270(45):26802-6
references: 7592920
references: Oncol Res. 2005;15(1):1-9
references: 15839301
references: J Clin Oncol. 2005 Feb 20;23(6):1061-9
references: 15657405
references: Mol Pharmacol. 1995 Jun;47(6):1106-11
references: 7603448
references: Br J Cancer. 2001 Apr 20;84(8):1126-34
references: 11308265
references: J Biol Chem. 2002 Mar 22;277(12):10678-82
references: 11788600
references: Br J Cancer. 2002 May 6;86(9):1479-86
references: 11986784
references: J Biol Chem. 1997 May 2;272(18):11671-3
references: 9115213
references: BMC Cancer. 2006 Mar 15;6:60
references: 16539721
references: Biochem J. 2000 Oct 15;351 Pt 2:289-305
references: 11023813
references: Biochem Biophys Res Commun. 1999 Oct 14;264(1):108-11
references: 10527849
references: Oncologist. 2005 Sep;10 (8):565-78
references: 16177281
references: Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1369-74
references: 9465021
references: J Bone Miner Res. 1998 Apr;13(4):581-9
references: 9556058
references: Prostate Cancer. 2012;2012:989214
references: 22111007
references: J Natl Cancer Inst. 1991 Feb 20;83(4):288-91
references: 1671606
references: BJU Int. 2004 Jul;94(1):164-70
references: 15217454
references: J Biol Chem. 2002 May 3;277(18):15309-16
references: 11839765
references: Br J Cancer. 2003 May 19;88(10):1631-40
references: 12771933
references: J Urol. 2003 Jul;170(1):246-52
references: 12796698
references: Urology. 1998 Aug;52(2):341-7
references: 9697810
references: Acta Oncol. 2007;46(5):669-77
references: 17562444
references: Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
references: 17126425
references: J Clin Invest. 1991 Dec;88(6):2095-105
references: 1661297